{"prompt": "['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', 'Colitis Adverse Event Management', 'COLITIS', 'REGN2810 Dosing', 'Diagnostic', 'Action and Guidelines', 'CTCAE v4.03 Grade', 'Management', 'Considerations', 'Patients with Grade 3 enterocolitis, drug will be', 'permanently discontinued and treatment with systemic', 'corticosteroids should be initiated at a dose of 1 to 2', 'mg/kg/day of prednisone or equivalent. When symptoms', 'improve to Grade 1 or less, corticosteroid taper should be', 'started and continued over at least 1 month.', 'All attempts should be', 'made to rule out other', 'For Grade 3-4 diarrhea (or Grade 2 diarrhea that persists', 'causes such as', 'Withhold REGN2810', 'after initial steroid treatment),', 'metastatic disease,', 'Rule out bowel perforation. Imaging with plain films or', 'bacterial or parasitic', 'Discontinue if unable', 'computed tomography (CT) can be useful.', 'infection, viral', 'Consider consultation with gastroenterologist and', 'to reduce', 'gastroenteritis, or the', 'confirmation biopsy with endoscopy.', 'Grade 3-4', 'corticosteroid dose to', 'first manifestation of', 'Treat with intravenous (IV) steroids (methylprednisolone', '<10 mg per day', '125 mg) followed by high-dose oral steroids (prednisone', 'an inflammatory', 'prednisone equivalent', '1-2 mg/kg once per day or dexamethasone 4 mg every 4', 'bowel disease by', 'within 12 weeks of', 'hours). When symptoms improve to grade 1 or less,', 'examination for stool', 'toxicity', 'steroid taper should be started and continued over no', 'leukocytes, stool', 'less than 4 weeks. Taper over 6-8 weeks in patients with', 'cultures, and a', 'diffuse and severe ulceration and/or bleeding.', 'Clostridium difficile', 'If IV steroids followed by high-dose oral steroids does not', 'titer', 'reduce initial symptoms within 48-72 hours, consider', 'treatment with infliximab at 5 mg/kg once every 2 weeks.', 'If symptoms are', 'Discontinue infliximab upon symptom relief and initiate a', 'persistent And/or', 'prolonged steroid taper over 45-60 days. If symptoms', 'severe, endoscopic', 'worsen during steroid reduction, initiate a retapering of', 'evaluation should be', 'steroids starting at a higher dose of 80 or 100 mg', 'considered', 'followed by a more prolonged taper and administer', 'infliximab. CAUTION: infliximab is contraindicated in', 'patients with bowel perforation or sepsis.', 'If symptoms persist despite the above treatment a', 'surgical consult should be obtained.', 'Regeneron Pharmaceuticals, Inc.', 'Page 120 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1.0 Approved - 14 Apr 2021 GMT-5:00']['R2810-ONC-1676 Amendment 7', 'Clinical Study Protocol', 'Endocrine Adverse Event Management', 'Diagnostic', 'ENDOCRINE', 'REGN2810 Dosing', 'Action and Guidelines', 'Considerations', 'EVENTS', 'Management', 'CTCAE v4.03 Grade', 'Monitor thyroid function or other hormonal level', 'Grade 1-2', 'tests and serum chemistries more frequently', 'Hyperthyroidism', 'No change in REGN2810', '(every 3-6 weeks) until returned to baseline', 'Hypothyroidism', 'dose', 'values.', 'Thyroid disorder', 'Replacement of thyroid hormone or thyroid', 'All attempts should', 'Thyroiditis', 'suppression therapy as indicated.', 'be made to rule out', 'other causes such as', 'brain metastases,', 'sepsis, and/or', 'infection. An', 'endocrinology', 'consultation is', 'recommended', 'Consider endocrine consultation.', 'Hold until on stable', 'Rule out infection and sepsis with appropriate', 'Grade 3-4', 'replacement dose as', 'cultures and imaging.', 'Hyperthyroidism', 'determined by', 'Replacement of thyroid hormone or thyroid', 'Hypothyroidism', 'resolution of', 'suppression therapy as indicated.', 'Thyroid disorder', 'symptoms and', 'Thyroiditis', 'normalization of', 'hormone levels.', 'Page 121 of 145', 'Regeneron Pharmaceuticals, Inc.', 'CONFIDENTIAL', 'VV-RIM-00146791-1.0 Approved - 14 Apr 2021 GMT-5:00']\n\n###\n\n", "completion": "END"}